The global market for Multiple Sclerosis Therapeutics was valued at US$ 17710 million in the year 2024 and is projected to reach a revised size of US$ 20310 million by 2031, growing at a CAGR of 2.0% during the forecast period.

Multiple Sclerosis Therapeutics Market

Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Therapeutics.

The Multiple Sclerosis Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Multiple Sclerosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Multiple Sclerosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.

Market Segmentation

Scope of Multiple Sclerosis Therapeutics Market Report

Report Metric	Details
Report Name	Multiple Sclerosis Therapeutics Market
Accounted market size in year	US$ 17710 million
Forecasted market size in 2031	US$ 20310 million
CAGR	2.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Beta Interferon Corticosteroids Monoclonal Antibodies Antineoplastic Agents Others
Segment by Distribution Channel	Hospital Pharmacies Retail Pharmacies e-Commerce
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck, AbbVie
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Sclerosis Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Multiple Sclerosis Therapeutics Market growing?

Ans: The Multiple Sclerosis Therapeutics Market witnessing a CAGR of 2.0% during the forecast period 2025-2031.

What is the Multiple Sclerosis Therapeutics Market size in 2031?

Ans: The Multiple Sclerosis Therapeutics Market size in 2031 will be US$ 20310 million.

Who are the main players in the Multiple Sclerosis Therapeutics Market report?

Ans: The main players in the Multiple Sclerosis Therapeutics Market are Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck, AbbVie

What are the Type segmentation covered in the Multiple Sclerosis Therapeutics Market report?

Ans: The Types covered in the Multiple Sclerosis Therapeutics Market report are Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Beta Interferon

1.2.3 Corticosteroids

1.2.4 Monoclonal Antibodies

1.2.5 Antineoplastic Agents

1.2.6 Others

1.3 Market by Distribution Channel

1.3.1 Global Multiple Sclerosis Therapeutics Market Growth by Distribution Channel: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 e-Commerce

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Multiple Sclerosis Therapeutics Market Perspective (2020-2031)

2.2 Global Multiple Sclerosis Therapeutics Growth Trends by Region

2.2.1 Global Multiple Sclerosis Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Multiple Sclerosis Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Multiple Sclerosis Therapeutics Market Dynamics

2.3.1 Multiple Sclerosis Therapeutics Industry Trends

2.3.2 Multiple Sclerosis Therapeutics Market Drivers

2.3.3 Multiple Sclerosis Therapeutics Market Challenges

2.3.4 Multiple Sclerosis Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue

3.1.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Multiple Sclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Multiple Sclerosis Therapeutics Revenue

3.4 Global Multiple Sclerosis Therapeutics Market Concentration Ratio

3.4.1 Global Multiple Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapeutics Revenue in 2024

3.5 Global Key Players of Multiple Sclerosis Therapeutics Head office and Area Served

3.6 Global Key Players of Multiple Sclerosis Therapeutics, Product and Application

3.7 Global Key Players of Multiple Sclerosis Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Multiple Sclerosis Therapeutics Breakdown Data by Type

4.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2026-2031)

5 Multiple Sclerosis Therapeutics Breakdown Data by Distribution Channel

5.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Distribution Channel (2020-2025)

5.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2026-2031)

6 North America

6.1 North America Multiple Sclerosis Therapeutics Market Size (2020-2031)

6.2 North America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Multiple Sclerosis Therapeutics Market Size by Country (2020-2025)

6.4 North America Multiple Sclerosis Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Multiple Sclerosis Therapeutics Market Size (2020-2031)

7.2 Europe Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Multiple Sclerosis Therapeutics Market Size by Country (2020-2025)

7.4 Europe Multiple Sclerosis Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Multiple Sclerosis Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Multiple Sclerosis Therapeutics Market Size (2020-2031)

9.2 Latin America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Multiple Sclerosis Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Multiple Sclerosis Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Multiple Sclerosis Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Multiple Sclerosis Therapeutics Introduction

11.1.4 Novartis Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Teva Pharmaceuticals

11.2.1 Teva Pharmaceuticals Company Details

11.2.2 Teva Pharmaceuticals Business Overview

11.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Introduction

11.2.4 Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.2.5 Teva Pharmaceuticals Recent Development

11.3 Sanofi Genzyme

11.3.1 Sanofi Genzyme Company Details

11.3.2 Sanofi Genzyme Business Overview

11.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Introduction

11.3.4 Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.3.5 Sanofi Genzyme Recent Development

11.4 Bayer

11.4.1 Bayer Company Details

11.4.2 Bayer Business Overview

11.4.3 Bayer Multiple Sclerosis Therapeutics Introduction

11.4.4 Bayer Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.4.5 Bayer Recent Development

11.5 Pfizer

11.5.1 Pfizer Company Details

11.5.2 Pfizer Business Overview

11.5.3 Pfizer Multiple Sclerosis Therapeutics Introduction

11.5.4 Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.5.5 Pfizer Recent Development

11.6 Biogen Idec

11.6.1 Biogen Idec Company Details

11.6.2 Biogen Idec Business Overview

11.6.3 Biogen Idec Multiple Sclerosis Therapeutics Introduction

11.6.4 Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.6.5 Biogen Idec Recent Development

11.7 Merck

11.7.1 Merck Company Details

11.7.2 Merck Business Overview

11.7.3 Merck Multiple Sclerosis Therapeutics Introduction

11.7.4 Merck Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.7.5 Merck Recent Development

11.8 AbbVie

11.8.1 AbbVie Company Details

11.8.2 AbbVie Business Overview

11.8.3 AbbVie Multiple Sclerosis Therapeutics Introduction

11.8.4 AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2020-2025)

11.8.5 AbbVie Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Beta Interferon

Table 3. Key Players of Corticosteroids

Table 4. Key Players of Monoclonal Antibodies

Table 5. Key Players of Antineoplastic Agents

Table 6. Key Players of Others

Table 7. Global Multiple Sclerosis Therapeutics Market Size Growth by Distribution Channel (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Multiple Sclerosis Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Multiple Sclerosis Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Multiple Sclerosis Therapeutics Market Share by Region (2020-2025)

Table 11. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Multiple Sclerosis Therapeutics Market Share by Region (2026-2031)

Table 13. Multiple Sclerosis Therapeutics Market Trends

Table 14. Multiple Sclerosis Therapeutics Market Drivers

Table 15. Multiple Sclerosis Therapeutics Market Challenges

Table 16. Multiple Sclerosis Therapeutics Market Restraints

Table 17. Global Multiple Sclerosis Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Multiple Sclerosis Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2024)

Table 20. Ranking of Global Top Multiple Sclerosis Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Multiple Sclerosis Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Multiple Sclerosis Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Multiple Sclerosis Therapeutics, Product and Application

Table 24. Global Key Players of Multiple Sclerosis Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Multiple Sclerosis Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Multiple Sclerosis Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2020-2025) & (US$ Million)

Table 31. Global Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2020-2025)

Table 32. Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2026-2031) & (US$ Million)

Table 33. Global Multiple Sclerosis Therapeutics Revenue Market Share by Distribution Channel (2026-2031)

Table 34. North America Multiple Sclerosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Multiple Sclerosis Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Multiple Sclerosis Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Multiple Sclerosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Multiple Sclerosis Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Multiple Sclerosis Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Multiple Sclerosis Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Multiple Sclerosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Multiple Sclerosis Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Multiple Sclerosis Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Multiple Sclerosis Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. Novartis Company Details

Table 50. Novartis Business Overview

Table 51. Novartis Multiple Sclerosis Therapeutics Product

Table 52. Novartis Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 53. Novartis Recent Development

Table 54. Teva Pharmaceuticals Company Details

Table 55. Teva Pharmaceuticals Business Overview

Table 56. Teva Pharmaceuticals Multiple Sclerosis Therapeutics Product

Table 57. Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 58. Teva Pharmaceuticals Recent Development

Table 59. Sanofi Genzyme Company Details

Table 60. Sanofi Genzyme Business Overview

Table 61. Sanofi Genzyme Multiple Sclerosis Therapeutics Product

Table 62. Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Sanofi Genzyme Recent Development

Table 64. Bayer Company Details

Table 65. Bayer Business Overview

Table 66. Bayer Multiple Sclerosis Therapeutics Product

Table 67. Bayer Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Bayer Recent Development

Table 69. Pfizer Company Details

Table 70. Pfizer Business Overview

Table 71. Pfizer Multiple Sclerosis Therapeutics Product

Table 72. Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 73. Pfizer Recent Development

Table 74. Biogen Idec Company Details

Table 75. Biogen Idec Business Overview

Table 76. Biogen Idec Multiple Sclerosis Therapeutics Product

Table 77. Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 78. Biogen Idec Recent Development

Table 79. Merck Company Details

Table 80. Merck Business Overview

Table 81. Merck Multiple Sclerosis Therapeutics Product

Table 82. Merck Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 83. Merck Recent Development

Table 84. AbbVie Company Details

Table 85. AbbVie Business Overview

Table 86. AbbVie Multiple Sclerosis Therapeutics Product

Table 87. AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2020-2025) & (US$ Million)

Table 88. AbbVie Recent Development

Table 89. Research Programs/Design for This Report

Table 90. Key Data Information from Secondary Sources

Table 91. Key Data Information from Primary Sources

Table 92. Authors List of This Report

List of Figures

Figure 1. Multiple Sclerosis Therapeutics Picture

Figure 2. Global Multiple Sclerosis Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Multiple Sclerosis Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Beta Interferon Features

Figure 5. Corticosteroids Features

Figure 6. Monoclonal Antibodies Features

Figure 7. Antineoplastic Agents Features

Figure 8. Others Features

Figure 9. Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel (2020-2031) & (US$ Million)

Figure 10. Global Multiple Sclerosis Therapeutics Market Share by Distribution Channel: 2024 VS 2031

Figure 11. Hospital Pharmacies Case Studies

Figure 12. Retail Pharmacies Case Studies

Figure 13. e-Commerce Case Studies

Figure 14. Multiple Sclerosis Therapeutics Report Years Considered

Figure 15. Global Multiple Sclerosis Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 16. Global Multiple Sclerosis Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Multiple Sclerosis Therapeutics Market Share by Region: 2024 VS 2031

Figure 18. Global Multiple Sclerosis Therapeutics Market Share by Players in 2024

Figure 19. Global Top Multiple Sclerosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2024)

Figure 20. The Top 10 and 5 Players Market Share by Multiple Sclerosis Therapeutics Revenue in 2024

Figure 21. North America Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. North America Multiple Sclerosis Therapeutics Market Share by Country (2020-2031)

Figure 23. United States Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Canada Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe Multiple Sclerosis Therapeutics Market Share by Country (2020-2031)

Figure 27. Germany Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. France Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. U.K. Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Italy Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Russia Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Nordic Countries Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific Multiple Sclerosis Therapeutics Market Share by Region (2020-2031)

Figure 35. China Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Japan Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. South Korea Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Southeast Asia Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. India Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Australia Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America Multiple Sclerosis Therapeutics Market Share by Country (2020-2031)

Figure 43. Mexico Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Brazil Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa Multiple Sclerosis Therapeutics Market Share by Country (2020-2031)

Figure 47. Turkey Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. UAE Multiple Sclerosis Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Novartis Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 51. Teva Pharmaceuticals Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 52. Sanofi Genzyme Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 53. Bayer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 54. Pfizer Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 55. Biogen Idec Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 56. Merck Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 57. AbbVie Revenue Growth Rate in Multiple Sclerosis Therapeutics Business (2020-2025)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions